Get the Stockscreener App
32.20
0.37%
0.12
After Hours:
32.20
Edgewise Therapeutics Inc stock is traded at $32.20, with a volume of 603.73K.
It is up +0.37% in the last 24 hours and down -7.95% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
See More
Previous Close:
$32.08
Open:
$33.16
24h Volume:
603.73K
Relative Volume:
0.55
Market Cap:
$3.07B
Revenue:
-
Net Income/Loss:
$-115.88M
P/E Ratio:
-24.03
EPS:
-1.34
Net Cash Flow:
$-104.72M
1W Performance:
+0.78%
1M Performance:
-7.95%
6M Performance:
+88.19%
1Y Performance:
+418.52%
1-Day Range:
$32.07
$33.94
1-Week Range:
$31.53
$33.94
52-Week Range:
$5.93
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
32.20 | 3.07B | 0 | -115.88M | -104.72M | -1.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Edgewise Therapeutics shares target lifted, buy rating on positive outlook By Investing.com - Investing.com UK
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 - BioSpace
Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation - Simply Wall St
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Evercore ISI Group Initiates Coverage of Edgewise Therapeutics (EWTX) with Outperform Recommendation - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Now Covered by Evercore ISI - MarketBeat
FY2024 Earnings Estimate for EWTX Issued By Leerink Partnrs - Defense World
What is Leerink Partnrs' Forecast for EWTX FY2024 Earnings? - MarketBeat
Orbimed Advisors LLC Adjusts Stake in Edgewise Therapeutics Inc - GuruFocus.com
FMR LLC Reduces Stake in Edgewise Therapeutics Inc - GuruFocus.com
Learn to Evaluate (EWTX) using the Charts - Stock Traders Daily
Edgewise Therapeutics Reports Third Quarter Financial Results and Business Highlights - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Price Target Raised to $45.00 - MarketBeat
Edgewise Therapeutics Reports Q3 Progress in Muscle Disease Trials - TipRanks
Edgewise Therapeutics Inc. (EWTX) Quarterly 10-Q Report - Quartzy
Edgewise boosts R&D spending with drug trials underway - BizWest
Edgewise Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - BioSpace
Edgewise Therapeutics stock hits 52-week high at $36.71 - Investing.com
Edgewise Therapeutics stock hits 52-week high at $36.71 By Investing.com - Investing.com UK
Critical Analysis: Prestige Consumer Healthcare (NYSE:PBH) versus Edgewise Therapeutics (NASDAQ:EWTX) - Defense World
abrdn plc Purchases Shares of 256,645 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics shares maintain price target on positive data By Investing.com - Investing.com Australia
Novo Holdings A S Sells 794,530 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Moody Aldrich Partners LLC Makes New Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics stock hits 52-week high at $35.34 By Investing.com - Investing.com Australia
Edgewise Therapeutics stock hits 52-week high at $35.34 - Investing.com
Edgewise Therapeutics Inc (EWTX)’s Market Momentum: Closing Strong at 32.99, Up 3.68 - The Dwinnex
Top investors say Edgewise Therapeutics Inc (EWTX) ticks everything they need - SETE News
Edgewise Therapeutics (NASDAQ:EWTX) Reaches New 52-Week HighShould You Buy? - MarketBeat
Is it possible to buy Edgewise Therapeutics Inc(EWTX) shares at a good price now? - US Post News
EWTX (Edgewise Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
SG Americas Securities LLC Sells 34,544 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Piper Sandler Increases Edgewise Therapeutics (NASDAQ:EWTX) Price Target to $51.00 - Defense World
Minimal stock impact anticipated for Edgewise Therapeutics stock even with potential CK miss - Investing.com Canada
Edgewise Therapeutics (NASDAQ:EWTX) Shares Up 4.5% Following Analyst Upgrade - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Price Target Raised to $51.00 at Piper Sandler - MarketBeat
(EWTX) Technical Pivots with Risk Controls - Stock Traders Daily
Edgewise Therapeutics Inc (EWTX) Stock: Navigating Drops and Gains - The InvestChronicle
Chief Scientific Officer Russell Alan J sold 75,000 shares of Edgewise Therapeutics Inc [EWTX] - Knox Daily
Edgewise Therapeutics (NASDAQ:EWTX) Hits New 12-Month HighTime to Buy? - MarketBeat
A look into Edgewise Therapeutics Inc (EWTX)’s deeper side - SETE News
Financial Analysis: Edgewise Therapeutics Inc (EWTX)’s Ratios Unveil Key Insights - The Dwinnex
Was there any good news for Edgewise Therapeutics Inc (EWTX) stock in the last session? - US Post News
Dimensional Fund Advisors LP Buys 168,219 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (EWTX): A Hot Stock to Buy Now - Yahoo Finance
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down – Here’s What Happened - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownHere's What Happened - MarketBeat
Edgewise Therapeutics Inc [EWTX] Insider Activity: An Update for Investors - Knox Daily
Squarepoint Ops LLC Purchases 27,687 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Millennium Management LLC Purchases 613,251 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Edgewise Therapeutics Inc Stock (EWTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer |
Sep 20 '24 |
Option Exercise |
0.18 |
75,000 |
13,500 |
87,719 |
| Russell Alan J | Chief Scientific Officer |
Sep 20 '24 |
Sale |
28.27 |
75,000 |
2,120,101 |
12,719 |
| MOORE JOHN R | General Counsel |
Sep 20 '24 |
Option Exercise |
0.71 |
50,000 |
35,500 |
53,252 |
| MOORE JOHN R | General Counsel |
Sep 23 '24 |
Option Exercise |
0.71 |
20,922 |
14,855 |
24,174 |
| MOORE JOHN R | General Counsel |
Sep 20 '24 |
Sale |
28.37 |
50,000 |
1,418,510 |
3,252 |
| MOORE JOHN R | General Counsel |
Sep 23 '24 |
Sale |
27.63 |
20,922 |
578,064 |
3,252 |
| Donovan Joanne M. | CMO |
Sep 20 '24 |
Sale |
28.29 |
7,162 |
202,603 |
14,538 |
| Derakhshan Behrad | Chief Business Officer |
Sep 20 '24 |
Option Exercise |
1.93 |
42,068 |
81,191 |
57,189 |
| Derakhshan Behrad | Chief Business Officer |
Sep 20 '24 |
Sale |
29.03 |
42,068 |
1,221,133 |
15,121 |
| Carruthers R Michael | Chief Financial Officer |
Sep 20 '24 |
Option Exercise |
1.93 |
96,068 |
185,411 |
81,996 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):